Renin–angiotensin–aldosterone system is an important regulator of renal and myocardial fibrosis, and drugs interfering with the renin–angiotensin–aldosterone system, as angiotensin converting enzyme (ACE) inhibitors and angiotensin type 1 receptor blockers, presently represent the tools of choice to counteract the progression of renal and cardiovascular diseases [13]. This evidence concerns the gene ACE and cardiovascular disorder.